Medline accuses competitor of confusing customers over COVID-19 PPE
A manufacturer of healthcare products including personal protective equipment has accused a newly incorporated company of trying to confuse consumers during the Covid-19 pandemic.
Ex-DuPont employee gets 42 months over trade secret theft
A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.
Ravgen and Myriad in patent dispute over DNA testing tech
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Fed Circuit refuses to revive Biogen’s MS drug dispute
Biogen has lost its long-standing fight to recover billions of dollars in royalties from the sale of a multiple sclerosis (MS) drug, after the US Court of Appeals for the Federal Circuit rejected Biogen’s request that it reconsider its own ruling.
US Congress confirms new drug patent listing law
A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.
Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
US ITC bars imports of low-cost Botox amid trade secrets dispute
The US International Trade Commission has sided in favour of AbbVie/Allergan, which argued that a rival should be prevented from importing a low-cost version of its Botox treatment into the US for 21 months, because it had stolen trade secrets.
Lawyers warn of Irish Sea split over SPCs
The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Eli Lilly seals $1bn genetics deal
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
Boston Scientific and Nevro conclude patent dispute
Medical device company Nevro has agreed to drop a patent infringement suit which accused Boston Scientific of infringing patents related to spinal cord stimulation (SCS) therapy.
